Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
45,497
archived clinical trials in
Breast Cancer

Effect of Zoledronic Acid as Anti-Cancer Treatment in Metastatic Breast Cancer Patients
A Multicenter, Open-label, Randomized Trial to Evaluate the Anti-cancer Effects of Zoledronic Acid Using Circulating Tumor Cell Measurements in Patients With Newly Diagnosed HER2-negative Metastatic Breast Cancer
Status: Archived
Doctors Medical Center, Cancer Center
mi
from
San Pablo, CA
Effect of Zoledronic Acid as Anti-Cancer Treatment in Metastatic Breast Cancer Patients
A Multicenter, Open-label, Randomized Trial to Evaluate the Anti-cancer Effects of Zoledronic Acid Using Circulating Tumor Cell Measurements in Patients With Newly Diagnosed HER2-negative Metastatic Breast Cancer
Status: Archived
Updated: 1/1/1970
Doctors Medical Center, Cancer Center
mi
from
San Pablo, CA
Effect of Zoledronic Acid as Anti-Cancer Treatment in Metastatic Breast Cancer Patients
A Multicenter, Open-label, Randomized Trial to Evaluate the Anti-cancer Effects of Zoledronic Acid Using Circulating Tumor Cell Measurements in Patients With Newly Diagnosed HER2-negative Metastatic Breast Cancer
Status: Archived
Holy Cross Hospital
mi
from
Fort Lauderdale, FL
Effect of Zoledronic Acid as Anti-Cancer Treatment in Metastatic Breast Cancer Patients
A Multicenter, Open-label, Randomized Trial to Evaluate the Anti-cancer Effects of Zoledronic Acid Using Circulating Tumor Cell Measurements in Patients With Newly Diagnosed HER2-negative Metastatic Breast Cancer
Status: Archived
Updated: 1/1/1970
Holy Cross Hospital
mi
from
Fort Lauderdale, FL
Effect of Zoledronic Acid as Anti-Cancer Treatment in Metastatic Breast Cancer Patients
A Multicenter, Open-label, Randomized Trial to Evaluate the Anti-cancer Effects of Zoledronic Acid Using Circulating Tumor Cell Measurements in Patients With Newly Diagnosed HER2-negative Metastatic Breast Cancer
Status: Archived
Florida Cancer Specialist
mi
from
Fort Myers, FL
Effect of Zoledronic Acid as Anti-Cancer Treatment in Metastatic Breast Cancer Patients
A Multicenter, Open-label, Randomized Trial to Evaluate the Anti-cancer Effects of Zoledronic Acid Using Circulating Tumor Cell Measurements in Patients With Newly Diagnosed HER2-negative Metastatic Breast Cancer
Status: Archived
Updated: 1/1/1970
Florida Cancer Specialist
mi
from
Fort Myers, FL
Effect of Zoledronic Acid as Anti-Cancer Treatment in Metastatic Breast Cancer Patients
A Multicenter, Open-label, Randomized Trial to Evaluate the Anti-cancer Effects of Zoledronic Acid Using Circulating Tumor Cell Measurements in Patients With Newly Diagnosed HER2-negative Metastatic Breast Cancer
Status: Archived
Cancer Care of North Florida, P.A.
mi
from
Lake City, FL
Effect of Zoledronic Acid as Anti-Cancer Treatment in Metastatic Breast Cancer Patients
A Multicenter, Open-label, Randomized Trial to Evaluate the Anti-cancer Effects of Zoledronic Acid Using Circulating Tumor Cell Measurements in Patients With Newly Diagnosed HER2-negative Metastatic Breast Cancer
Status: Archived
Updated: 1/1/1970
Cancer Care of North Florida, P.A.
mi
from
Lake City, FL
Effect of Zoledronic Acid as Anti-Cancer Treatment in Metastatic Breast Cancer Patients
A Multicenter, Open-label, Randomized Trial to Evaluate the Anti-cancer Effects of Zoledronic Acid Using Circulating Tumor Cell Measurements in Patients With Newly Diagnosed HER2-negative Metastatic Breast Cancer
Status: Archived
Lakeland Regional Cancer Care Center - St. Joseph
mi
from
St. Joseph, MI
Effect of Zoledronic Acid as Anti-Cancer Treatment in Metastatic Breast Cancer Patients
A Multicenter, Open-label, Randomized Trial to Evaluate the Anti-cancer Effects of Zoledronic Acid Using Circulating Tumor Cell Measurements in Patients With Newly Diagnosed HER2-negative Metastatic Breast Cancer
Status: Archived
Updated: 1/1/1970
Lakeland Regional Cancer Care Center - St. Joseph
mi
from
St. Joseph, MI
Effect of Zoledronic Acid as Anti-Cancer Treatment in Metastatic Breast Cancer Patients
A Multicenter, Open-label, Randomized Trial to Evaluate the Anti-cancer Effects of Zoledronic Acid Using Circulating Tumor Cell Measurements in Patients With Newly Diagnosed HER2-negative Metastatic Breast Cancer
Status: Archived
Hematology Oncology Associates
mi
from
Lake Worth, FL
Effect of Zoledronic Acid as Anti-Cancer Treatment in Metastatic Breast Cancer Patients
A Multicenter, Open-label, Randomized Trial to Evaluate the Anti-cancer Effects of Zoledronic Acid Using Circulating Tumor Cell Measurements in Patients With Newly Diagnosed HER2-negative Metastatic Breast Cancer
Status: Archived
Updated: 1/1/1970
Hematology Oncology Associates
mi
from
Lake Worth, FL
Effect of Zoledronic Acid as Anti-Cancer Treatment in Metastatic Breast Cancer Patients
A Multicenter, Open-label, Randomized Trial to Evaluate the Anti-cancer Effects of Zoledronic Acid Using Circulating Tumor Cell Measurements in Patients With Newly Diagnosed HER2-negative Metastatic Breast Cancer
Status: Archived
Pasco Hernando Oncology Associates P.A
mi
from
Brooksville, FL
Effect of Zoledronic Acid as Anti-Cancer Treatment in Metastatic Breast Cancer Patients
A Multicenter, Open-label, Randomized Trial to Evaluate the Anti-cancer Effects of Zoledronic Acid Using Circulating Tumor Cell Measurements in Patients With Newly Diagnosed HER2-negative Metastatic Breast Cancer
Status: Archived
Updated: 1/1/1970
Pasco Hernando Oncology Associates P.A
mi
from
Brooksville, FL
Effect of Zoledronic Acid as Anti-Cancer Treatment in Metastatic Breast Cancer Patients
A Multicenter, Open-label, Randomized Trial to Evaluate the Anti-cancer Effects of Zoledronic Acid Using Circulating Tumor Cell Measurements in Patients With Newly Diagnosed HER2-negative Metastatic Breast Cancer
Status: Archived
Space Coast Cancer Center
mi
from
Titusville, FL
Effect of Zoledronic Acid as Anti-Cancer Treatment in Metastatic Breast Cancer Patients
A Multicenter, Open-label, Randomized Trial to Evaluate the Anti-cancer Effects of Zoledronic Acid Using Circulating Tumor Cell Measurements in Patients With Newly Diagnosed HER2-negative Metastatic Breast Cancer
Status: Archived
Updated: 1/1/1970
Space Coast Cancer Center
mi
from
Titusville, FL
Effect of Zoledronic Acid as Anti-Cancer Treatment in Metastatic Breast Cancer Patients
A Multicenter, Open-label, Randomized Trial to Evaluate the Anti-cancer Effects of Zoledronic Acid Using Circulating Tumor Cell Measurements in Patients With Newly Diagnosed HER2-negative Metastatic Breast Cancer
Status: Archived
Straub Clinic And Hospital
mi
from
Honolulu, HI
Effect of Zoledronic Acid as Anti-Cancer Treatment in Metastatic Breast Cancer Patients
A Multicenter, Open-label, Randomized Trial to Evaluate the Anti-cancer Effects of Zoledronic Acid Using Circulating Tumor Cell Measurements in Patients With Newly Diagnosed HER2-negative Metastatic Breast Cancer
Status: Archived
Updated: 1/1/1970
Straub Clinic And Hospital
mi
from
Honolulu, HI
Effect of Zoledronic Acid as Anti-Cancer Treatment in Metastatic Breast Cancer Patients
A Multicenter, Open-label, Randomized Trial to Evaluate the Anti-cancer Effects of Zoledronic Acid Using Circulating Tumor Cell Measurements in Patients With Newly Diagnosed HER2-negative Metastatic Breast Cancer
Status: Archived
Kaiser Foundation Hospital-San Diego
mi
from
San Diego, CA
Effect of Zoledronic Acid as Anti-Cancer Treatment in Metastatic Breast Cancer Patients
A Multicenter, Open-label, Randomized Trial to Evaluate the Anti-cancer Effects of Zoledronic Acid Using Circulating Tumor Cell Measurements in Patients With Newly Diagnosed HER2-negative Metastatic Breast Cancer
Status: Archived
Updated: 1/1/1970
Kaiser Foundation Hospital-San Diego
mi
from
San Diego, CA
Effect of Zoledronic Acid as Anti-Cancer Treatment in Metastatic Breast Cancer Patients
A Multicenter, Open-label, Randomized Trial to Evaluate the Anti-cancer Effects of Zoledronic Acid Using Circulating Tumor Cell Measurements in Patients With Newly Diagnosed HER2-negative Metastatic Breast Cancer
Status: Archived
Kootenai Cancer Center
mi
from
Coeur d'Alene, ID
Effect of Zoledronic Acid as Anti-Cancer Treatment in Metastatic Breast Cancer Patients
A Multicenter, Open-label, Randomized Trial to Evaluate the Anti-cancer Effects of Zoledronic Acid Using Circulating Tumor Cell Measurements in Patients With Newly Diagnosed HER2-negative Metastatic Breast Cancer
Status: Archived
Updated: 1/1/1970
Kootenai Cancer Center
mi
from
Coeur d'Alene, ID
Effect of Zoledronic Acid as Anti-Cancer Treatment in Metastatic Breast Cancer Patients
A Multicenter, Open-label, Randomized Trial to Evaluate the Anti-cancer Effects of Zoledronic Acid Using Circulating Tumor Cell Measurements in Patients With Newly Diagnosed HER2-negative Metastatic Breast Cancer
Status: Archived
Oncology Specialist, SC
mi
from
Park Ridge, IL
Effect of Zoledronic Acid as Anti-Cancer Treatment in Metastatic Breast Cancer Patients
A Multicenter, Open-label, Randomized Trial to Evaluate the Anti-cancer Effects of Zoledronic Acid Using Circulating Tumor Cell Measurements in Patients With Newly Diagnosed HER2-negative Metastatic Breast Cancer
Status: Archived
Updated: 1/1/1970
Oncology Specialist, SC
mi
from
Park Ridge, IL
Effect of Zoledronic Acid as Anti-Cancer Treatment in Metastatic Breast Cancer Patients
A Multicenter, Open-label, Randomized Trial to Evaluate the Anti-cancer Effects of Zoledronic Acid Using Circulating Tumor Cell Measurements in Patients With Newly Diagnosed HER2-negative Metastatic Breast Cancer
Status: Archived
Cancer Center of Kansas
mi
from
Wichita, KA
Effect of Zoledronic Acid as Anti-Cancer Treatment in Metastatic Breast Cancer Patients
A Multicenter, Open-label, Randomized Trial to Evaluate the Anti-cancer Effects of Zoledronic Acid Using Circulating Tumor Cell Measurements in Patients With Newly Diagnosed HER2-negative Metastatic Breast Cancer
Status: Archived
Updated: 1/1/1970
Cancer Center of Kansas
mi
from
Wichita, KA
Effect of Zoledronic Acid as Anti-Cancer Treatment in Metastatic Breast Cancer Patients
A Multicenter, Open-label, Randomized Trial to Evaluate the Anti-cancer Effects of Zoledronic Acid Using Circulating Tumor Cell Measurements in Patients With Newly Diagnosed HER2-negative Metastatic Breast Cancer
Status: Archived
Peninsula Regional Medical Center
mi
from
Salisbury, MD
Effect of Zoledronic Acid as Anti-Cancer Treatment in Metastatic Breast Cancer Patients
A Multicenter, Open-label, Randomized Trial to Evaluate the Anti-cancer Effects of Zoledronic Acid Using Circulating Tumor Cell Measurements in Patients With Newly Diagnosed HER2-negative Metastatic Breast Cancer
Status: Archived
Updated: 1/1/1970
Peninsula Regional Medical Center
mi
from
Salisbury, MD
Effect of Zoledronic Acid as Anti-Cancer Treatment in Metastatic Breast Cancer Patients
A Multicenter, Open-label, Randomized Trial to Evaluate the Anti-cancer Effects of Zoledronic Acid Using Circulating Tumor Cell Measurements in Patients With Newly Diagnosed HER2-negative Metastatic Breast Cancer
Status: Archived
Saints Medical Center
mi
from
Lowell, MA
Effect of Zoledronic Acid as Anti-Cancer Treatment in Metastatic Breast Cancer Patients
A Multicenter, Open-label, Randomized Trial to Evaluate the Anti-cancer Effects of Zoledronic Acid Using Circulating Tumor Cell Measurements in Patients With Newly Diagnosed HER2-negative Metastatic Breast Cancer
Status: Archived
Updated: 1/1/1970
Saints Medical Center
mi
from
Lowell, MA
Effect of Zoledronic Acid as Anti-Cancer Treatment in Metastatic Breast Cancer Patients
A Multicenter, Open-label, Randomized Trial to Evaluate the Anti-cancer Effects of Zoledronic Acid Using Circulating Tumor Cell Measurements in Patients With Newly Diagnosed HER2-negative Metastatic Breast Cancer
Status: Archived
Haematology-Oncology Associates of Ohio and Michigan, PC
mi
from
Lambertville, MI
Effect of Zoledronic Acid as Anti-Cancer Treatment in Metastatic Breast Cancer Patients
A Multicenter, Open-label, Randomized Trial to Evaluate the Anti-cancer Effects of Zoledronic Acid Using Circulating Tumor Cell Measurements in Patients With Newly Diagnosed HER2-negative Metastatic Breast Cancer
Status: Archived
Updated: 1/1/1970
Haematology-Oncology Associates of Ohio and Michigan, PC
mi
from
Lambertville, MI
Effect of Zoledronic Acid as Anti-Cancer Treatment in Metastatic Breast Cancer Patients
A Multicenter, Open-label, Randomized Trial to Evaluate the Anti-cancer Effects of Zoledronic Acid Using Circulating Tumor Cell Measurements in Patients With Newly Diagnosed HER2-negative Metastatic Breast Cancer
Status: Archived
St. John's Pediatrics
mi
from
Leavenworth, KA
Effect of Zoledronic Acid as Anti-Cancer Treatment in Metastatic Breast Cancer Patients
A Multicenter, Open-label, Randomized Trial to Evaluate the Anti-cancer Effects of Zoledronic Acid Using Circulating Tumor Cell Measurements in Patients With Newly Diagnosed HER2-negative Metastatic Breast Cancer
Status: Archived
Updated: 1/1/1970
St. John's Pediatrics
mi
from
Leavenworth, KA
Effect of Zoledronic Acid as Anti-Cancer Treatment in Metastatic Breast Cancer Patients
A Multicenter, Open-label, Randomized Trial to Evaluate the Anti-cancer Effects of Zoledronic Acid Using Circulating Tumor Cell Measurements in Patients With Newly Diagnosed HER2-negative Metastatic Breast Cancer
Status: Archived
Southeast Nebraska Cancer Center
mi
from
Lincoln, NE
Effect of Zoledronic Acid as Anti-Cancer Treatment in Metastatic Breast Cancer Patients
A Multicenter, Open-label, Randomized Trial to Evaluate the Anti-cancer Effects of Zoledronic Acid Using Circulating Tumor Cell Measurements in Patients With Newly Diagnosed HER2-negative Metastatic Breast Cancer
Status: Archived
Updated: 1/1/1970
Southeast Nebraska Cancer Center
mi
from
Lincoln, NE
Effect of Zoledronic Acid as Anti-Cancer Treatment in Metastatic Breast Cancer Patients
A Multicenter, Open-label, Randomized Trial to Evaluate the Anti-cancer Effects of Zoledronic Acid Using Circulating Tumor Cell Measurements in Patients With Newly Diagnosed HER2-negative Metastatic Breast Cancer
Status: Archived
Reno Oncology Associates
mi
from
Reno, NV
Effect of Zoledronic Acid as Anti-Cancer Treatment in Metastatic Breast Cancer Patients
A Multicenter, Open-label, Randomized Trial to Evaluate the Anti-cancer Effects of Zoledronic Acid Using Circulating Tumor Cell Measurements in Patients With Newly Diagnosed HER2-negative Metastatic Breast Cancer
Status: Archived
Updated: 1/1/1970
Reno Oncology Associates
mi
from
Reno, NV
Effect of Zoledronic Acid as Anti-Cancer Treatment in Metastatic Breast Cancer Patients
A Multicenter, Open-label, Randomized Trial to Evaluate the Anti-cancer Effects of Zoledronic Acid Using Circulating Tumor Cell Measurements in Patients With Newly Diagnosed HER2-negative Metastatic Breast Cancer
Status: Archived
Hematology-Oncology Associates of Northern NJ, PA Carol G. Simon Cancer Center
mi
from
Morristown, NJ
Effect of Zoledronic Acid as Anti-Cancer Treatment in Metastatic Breast Cancer Patients
A Multicenter, Open-label, Randomized Trial to Evaluate the Anti-cancer Effects of Zoledronic Acid Using Circulating Tumor Cell Measurements in Patients With Newly Diagnosed HER2-negative Metastatic Breast Cancer
Status: Archived
Updated: 1/1/1970
Hematology-Oncology Associates of Northern NJ, PA Carol G. Simon Cancer Center
mi
from
Morristown, NJ
Effect of Zoledronic Acid as Anti-Cancer Treatment in Metastatic Breast Cancer Patients
A Multicenter, Open-label, Randomized Trial to Evaluate the Anti-cancer Effects of Zoledronic Acid Using Circulating Tumor Cell Measurements in Patients With Newly Diagnosed HER2-negative Metastatic Breast Cancer
Status: Archived
Somerset Hematology Oncology Associates
mi
from
Somerville, NJ
Effect of Zoledronic Acid as Anti-Cancer Treatment in Metastatic Breast Cancer Patients
A Multicenter, Open-label, Randomized Trial to Evaluate the Anti-cancer Effects of Zoledronic Acid Using Circulating Tumor Cell Measurements in Patients With Newly Diagnosed HER2-negative Metastatic Breast Cancer
Status: Archived
Updated: 1/1/1970
Somerset Hematology Oncology Associates
mi
from
Somerville, NJ
Effect of Zoledronic Acid as Anti-Cancer Treatment in Metastatic Breast Cancer Patients
A Multicenter, Open-label, Randomized Trial to Evaluate the Anti-cancer Effects of Zoledronic Acid Using Circulating Tumor Cell Measurements in Patients With Newly Diagnosed HER2-negative Metastatic Breast Cancer
Status: Archived
Clinical Research Alliance, Inc.
mi
from
Lake Success, NY
Effect of Zoledronic Acid as Anti-Cancer Treatment in Metastatic Breast Cancer Patients
A Multicenter, Open-label, Randomized Trial to Evaluate the Anti-cancer Effects of Zoledronic Acid Using Circulating Tumor Cell Measurements in Patients With Newly Diagnosed HER2-negative Metastatic Breast Cancer
Status: Archived
Updated: 1/1/1970
Clinical Research Alliance, Inc.
mi
from
Lake Success, NY
Effect of Zoledronic Acid as Anti-Cancer Treatment in Metastatic Breast Cancer Patients
A Multicenter, Open-label, Randomized Trial to Evaluate the Anti-cancer Effects of Zoledronic Acid Using Circulating Tumor Cell Measurements in Patients With Newly Diagnosed HER2-negative Metastatic Breast Cancer
Status: Archived
Hematology Oncology Associates of Rockland
mi
from
Nyack, NY
Effect of Zoledronic Acid as Anti-Cancer Treatment in Metastatic Breast Cancer Patients
A Multicenter, Open-label, Randomized Trial to Evaluate the Anti-cancer Effects of Zoledronic Acid Using Circulating Tumor Cell Measurements in Patients With Newly Diagnosed HER2-negative Metastatic Breast Cancer
Status: Archived
Updated: 1/1/1970
Hematology Oncology Associates of Rockland
mi
from
Nyack, NY
Effect of Zoledronic Acid as Anti-Cancer Treatment in Metastatic Breast Cancer Patients
A Multicenter, Open-label, Randomized Trial to Evaluate the Anti-cancer Effects of Zoledronic Acid Using Circulating Tumor Cell Measurements in Patients With Newly Diagnosed HER2-negative Metastatic Breast Cancer
Status: Archived
Piedmont Hematology Oncology
mi
from
Winston-Salem, NC
Effect of Zoledronic Acid as Anti-Cancer Treatment in Metastatic Breast Cancer Patients
A Multicenter, Open-label, Randomized Trial to Evaluate the Anti-cancer Effects of Zoledronic Acid Using Circulating Tumor Cell Measurements in Patients With Newly Diagnosed HER2-negative Metastatic Breast Cancer
Status: Archived
Updated: 1/1/1970
Piedmont Hematology Oncology
mi
from
Winston-Salem, NC
Effect of Zoledronic Acid as Anti-Cancer Treatment in Metastatic Breast Cancer Patients
A Multicenter, Open-label, Randomized Trial to Evaluate the Anti-cancer Effects of Zoledronic Acid Using Circulating Tumor Cell Measurements in Patients With Newly Diagnosed HER2-negative Metastatic Breast Cancer
Status: Archived
Penn State Milton S. Hershey Medical Center
mi
from
Hershey, PA
Effect of Zoledronic Acid as Anti-Cancer Treatment in Metastatic Breast Cancer Patients
A Multicenter, Open-label, Randomized Trial to Evaluate the Anti-cancer Effects of Zoledronic Acid Using Circulating Tumor Cell Measurements in Patients With Newly Diagnosed HER2-negative Metastatic Breast Cancer
Status: Archived
Updated: 1/1/1970
Penn State Milton S. Hershey Medical Center
mi
from
Hershey, PA
Effect of Zoledronic Acid as Anti-Cancer Treatment in Metastatic Breast Cancer Patients
A Multicenter, Open-label, Randomized Trial to Evaluate the Anti-cancer Effects of Zoledronic Acid Using Circulating Tumor Cell Measurements in Patients With Newly Diagnosed HER2-negative Metastatic Breast Cancer
Status: Archived
Berks Hematology Oncology Associates
mi
from
W Reading, PA
Effect of Zoledronic Acid as Anti-Cancer Treatment in Metastatic Breast Cancer Patients
A Multicenter, Open-label, Randomized Trial to Evaluate the Anti-cancer Effects of Zoledronic Acid Using Circulating Tumor Cell Measurements in Patients With Newly Diagnosed HER2-negative Metastatic Breast Cancer
Status: Archived
Updated: 1/1/1970
Berks Hematology Oncology Associates
mi
from
W Reading, PA
Effect of Zoledronic Acid as Anti-Cancer Treatment in Metastatic Breast Cancer Patients
A Multicenter, Open-label, Randomized Trial to Evaluate the Anti-cancer Effects of Zoledronic Acid Using Circulating Tumor Cell Measurements in Patients With Newly Diagnosed HER2-negative Metastatic Breast Cancer
Status: Archived
Abington Hematology Oncology Associates
mi
from
Willow Grove, PA
Effect of Zoledronic Acid as Anti-Cancer Treatment in Metastatic Breast Cancer Patients
A Multicenter, Open-label, Randomized Trial to Evaluate the Anti-cancer Effects of Zoledronic Acid Using Circulating Tumor Cell Measurements in Patients With Newly Diagnosed HER2-negative Metastatic Breast Cancer
Status: Archived
Updated: 1/1/1970
Abington Hematology Oncology Associates
mi
from
Willow Grove, PA
Effect of Zoledronic Acid as Anti-Cancer Treatment in Metastatic Breast Cancer Patients
A Multicenter, Open-label, Randomized Trial to Evaluate the Anti-cancer Effects of Zoledronic Acid Using Circulating Tumor Cell Measurements in Patients With Newly Diagnosed HER2-negative Metastatic Breast Cancer
Status: Archived
The West Clinic, PC
mi
from
Memphis, TN
Effect of Zoledronic Acid as Anti-Cancer Treatment in Metastatic Breast Cancer Patients
A Multicenter, Open-label, Randomized Trial to Evaluate the Anti-cancer Effects of Zoledronic Acid Using Circulating Tumor Cell Measurements in Patients With Newly Diagnosed HER2-negative Metastatic Breast Cancer
Status: Archived
Updated: 1/1/1970
The West Clinic, PC
mi
from
Memphis, TN
Effect of Zoledronic Acid as Anti-Cancer Treatment in Metastatic Breast Cancer Patients
A Multicenter, Open-label, Randomized Trial to Evaluate the Anti-cancer Effects of Zoledronic Acid Using Circulating Tumor Cell Measurements in Patients With Newly Diagnosed HER2-negative Metastatic Breast Cancer
Status: Archived
South Texas Oncology and Hematology
mi
from
San Antonio, TX
Effect of Zoledronic Acid as Anti-Cancer Treatment in Metastatic Breast Cancer Patients
A Multicenter, Open-label, Randomized Trial to Evaluate the Anti-cancer Effects of Zoledronic Acid Using Circulating Tumor Cell Measurements in Patients With Newly Diagnosed HER2-negative Metastatic Breast Cancer
Status: Archived
Updated: 1/1/1970
South Texas Oncology and Hematology
mi
from
San Antonio, TX
Effect of Zoledronic Acid as Anti-Cancer Treatment in Metastatic Breast Cancer Patients
A Multicenter, Open-label, Randomized Trial to Evaluate the Anti-cancer Effects of Zoledronic Acid Using Circulating Tumor Cell Measurements in Patients With Newly Diagnosed HER2-negative Metastatic Breast Cancer
Status: Archived
Tyler Hematology Oncology PA
mi
from
Tyler, TX
Effect of Zoledronic Acid as Anti-Cancer Treatment in Metastatic Breast Cancer Patients
A Multicenter, Open-label, Randomized Trial to Evaluate the Anti-cancer Effects of Zoledronic Acid Using Circulating Tumor Cell Measurements in Patients With Newly Diagnosed HER2-negative Metastatic Breast Cancer
Status: Archived
Updated: 1/1/1970
Tyler Hematology Oncology PA
mi
from
Tyler, TX
Effect of Zoledronic Acid as Anti-Cancer Treatment in Metastatic Breast Cancer Patients
A Multicenter, Open-label, Randomized Trial to Evaluate the Anti-cancer Effects of Zoledronic Acid Using Circulating Tumor Cell Measurements in Patients With Newly Diagnosed HER2-negative Metastatic Breast Cancer
Status: Archived
Blood And Cancer Center of East Texas
mi
from
Tyler, TX
Effect of Zoledronic Acid as Anti-Cancer Treatment in Metastatic Breast Cancer Patients
A Multicenter, Open-label, Randomized Trial to Evaluate the Anti-cancer Effects of Zoledronic Acid Using Circulating Tumor Cell Measurements in Patients With Newly Diagnosed HER2-negative Metastatic Breast Cancer
Status: Archived
Updated: 1/1/1970
Blood And Cancer Center of East Texas
mi
from
Tyler, TX
Effect of Zoledronic Acid as Anti-Cancer Treatment in Metastatic Breast Cancer Patients
A Multicenter, Open-label, Randomized Trial to Evaluate the Anti-cancer Effects of Zoledronic Acid Using Circulating Tumor Cell Measurements in Patients With Newly Diagnosed HER2-negative Metastatic Breast Cancer
Status: Archived
Central Utah Clinic, PC
mi
from
Provo, UT
Effect of Zoledronic Acid as Anti-Cancer Treatment in Metastatic Breast Cancer Patients
A Multicenter, Open-label, Randomized Trial to Evaluate the Anti-cancer Effects of Zoledronic Acid Using Circulating Tumor Cell Measurements in Patients With Newly Diagnosed HER2-negative Metastatic Breast Cancer
Status: Archived
Updated: 1/1/1970
Central Utah Clinic, PC
mi
from
Provo, UT
Effect of Zoledronic Acid as Anti-Cancer Treatment in Metastatic Breast Cancer Patients
A Multicenter, Open-label, Randomized Trial to Evaluate the Anti-cancer Effects of Zoledronic Acid Using Circulating Tumor Cell Measurements in Patients With Newly Diagnosed HER2-negative Metastatic Breast Cancer
Status: Archived
Medical Oncology and Hematology Associates of Northern Virginia, LTD
mi
from
Faifax, VA
Effect of Zoledronic Acid as Anti-Cancer Treatment in Metastatic Breast Cancer Patients
A Multicenter, Open-label, Randomized Trial to Evaluate the Anti-cancer Effects of Zoledronic Acid Using Circulating Tumor Cell Measurements in Patients With Newly Diagnosed HER2-negative Metastatic Breast Cancer
Status: Archived
Updated: 1/1/1970
Medical Oncology and Hematology Associates of Northern Virginia, LTD
mi
from
Faifax, VA
Effect of Zoledronic Acid as Anti-Cancer Treatment in Metastatic Breast Cancer Patients
A Multicenter, Open-label, Randomized Trial to Evaluate the Anti-cancer Effects of Zoledronic Acid Using Circulating Tumor Cell Measurements in Patients With Newly Diagnosed HER2-negative Metastatic Breast Cancer
Status: Archived
Providence Everett Medical Center
mi
from
Everett, WA
Effect of Zoledronic Acid as Anti-Cancer Treatment in Metastatic Breast Cancer Patients
A Multicenter, Open-label, Randomized Trial to Evaluate the Anti-cancer Effects of Zoledronic Acid Using Circulating Tumor Cell Measurements in Patients With Newly Diagnosed HER2-negative Metastatic Breast Cancer
Status: Archived
Updated: 1/1/1970
Providence Everett Medical Center
mi
from
Everett, WA
Effect of Zoledronic Acid as Anti-Cancer Treatment in Metastatic Breast Cancer Patients
A Multicenter, Open-label, Randomized Trial to Evaluate the Anti-cancer Effects of Zoledronic Acid Using Circulating Tumor Cell Measurements in Patients With Newly Diagnosed HER2-negative Metastatic Breast Cancer
Status: Archived
Northwest Medical Specialists
mi
from
Tacoma, WA
Effect of Zoledronic Acid as Anti-Cancer Treatment in Metastatic Breast Cancer Patients
A Multicenter, Open-label, Randomized Trial to Evaluate the Anti-cancer Effects of Zoledronic Acid Using Circulating Tumor Cell Measurements in Patients With Newly Diagnosed HER2-negative Metastatic Breast Cancer
Status: Archived
Updated: 1/1/1970
Northwest Medical Specialists
mi
from
Tacoma, WA
A Phase II, Randomized, Open-label Study of Lapatinib Plus Chemotherapy Versus Trastuzumab Plus Chemotherapy in HER2-positive and p95HER2-positive Metastatic Breast Cancer
A Phase II, Randomized, Open-label Study of Lapatinib Plus Chemotherapy Versus Trastuzumab Plus Chemotherapy as First-line Treatment for Women With HER2-positive and p95HER2-positive Metastatic Breast Cancer
Status: Archived
GSK Investigational Site
mi
from
Glendale, AZ
A Phase II, Randomized, Open-label Study of Lapatinib Plus Chemotherapy Versus Trastuzumab Plus Chemotherapy in HER2-positive and p95HER2-positive Metastatic Breast Cancer
A Phase II, Randomized, Open-label Study of Lapatinib Plus Chemotherapy Versus Trastuzumab Plus Chemotherapy as First-line Treatment for Women With HER2-positive and p95HER2-positive Metastatic Breast Cancer
Status: Archived
Updated: 1/1/1970
GSK Investigational Site
mi
from
Glendale, AZ
A Phase II, Randomized, Open-label Study of Lapatinib Plus Chemotherapy Versus Trastuzumab Plus Chemotherapy in HER2-positive and p95HER2-positive Metastatic Breast Cancer
A Phase II, Randomized, Open-label Study of Lapatinib Plus Chemotherapy Versus Trastuzumab Plus Chemotherapy as First-line Treatment for Women With HER2-positive and p95HER2-positive Metastatic Breast Cancer
Status: Archived
GSK Investigational Site
mi
from
Anaheim, CA
A Phase II, Randomized, Open-label Study of Lapatinib Plus Chemotherapy Versus Trastuzumab Plus Chemotherapy in HER2-positive and p95HER2-positive Metastatic Breast Cancer
A Phase II, Randomized, Open-label Study of Lapatinib Plus Chemotherapy Versus Trastuzumab Plus Chemotherapy as First-line Treatment for Women With HER2-positive and p95HER2-positive Metastatic Breast Cancer
Status: Archived
Updated: 1/1/1970
GSK Investigational Site
mi
from
Anaheim, CA
A Phase II, Randomized, Open-label Study of Lapatinib Plus Chemotherapy Versus Trastuzumab Plus Chemotherapy in HER2-positive and p95HER2-positive Metastatic Breast Cancer
A Phase II, Randomized, Open-label Study of Lapatinib Plus Chemotherapy Versus Trastuzumab Plus Chemotherapy as First-line Treatment for Women With HER2-positive and p95HER2-positive Metastatic Breast Cancer
Status: Archived
GSK Investigational Site
mi
from
Aurora, CO
A Phase II, Randomized, Open-label Study of Lapatinib Plus Chemotherapy Versus Trastuzumab Plus Chemotherapy in HER2-positive and p95HER2-positive Metastatic Breast Cancer
A Phase II, Randomized, Open-label Study of Lapatinib Plus Chemotherapy Versus Trastuzumab Plus Chemotherapy as First-line Treatment for Women With HER2-positive and p95HER2-positive Metastatic Breast Cancer
Status: Archived
Updated: 1/1/1970
GSK Investigational Site
mi
from
Aurora, CO
A Phase II, Randomized, Open-label Study of Lapatinib Plus Chemotherapy Versus Trastuzumab Plus Chemotherapy in HER2-positive and p95HER2-positive Metastatic Breast Cancer
A Phase II, Randomized, Open-label Study of Lapatinib Plus Chemotherapy Versus Trastuzumab Plus Chemotherapy as First-line Treatment for Women With HER2-positive and p95HER2-positive Metastatic Breast Cancer
Status: Archived
GSK Investigational Site
mi
from
New Haven, CT
A Phase II, Randomized, Open-label Study of Lapatinib Plus Chemotherapy Versus Trastuzumab Plus Chemotherapy in HER2-positive and p95HER2-positive Metastatic Breast Cancer
A Phase II, Randomized, Open-label Study of Lapatinib Plus Chemotherapy Versus Trastuzumab Plus Chemotherapy as First-line Treatment for Women With HER2-positive and p95HER2-positive Metastatic Breast Cancer
Status: Archived
Updated: 1/1/1970
GSK Investigational Site
mi
from
New Haven, CT
A Phase II, Randomized, Open-label Study of Lapatinib Plus Chemotherapy Versus Trastuzumab Plus Chemotherapy in HER2-positive and p95HER2-positive Metastatic Breast Cancer
A Phase II, Randomized, Open-label Study of Lapatinib Plus Chemotherapy Versus Trastuzumab Plus Chemotherapy as First-line Treatment for Women With HER2-positive and p95HER2-positive Metastatic Breast Cancer
Status: Archived
GSK Investigational Site
mi
from
Washington,
A Phase II, Randomized, Open-label Study of Lapatinib Plus Chemotherapy Versus Trastuzumab Plus Chemotherapy in HER2-positive and p95HER2-positive Metastatic Breast Cancer
A Phase II, Randomized, Open-label Study of Lapatinib Plus Chemotherapy Versus Trastuzumab Plus Chemotherapy as First-line Treatment for Women With HER2-positive and p95HER2-positive Metastatic Breast Cancer
Status: Archived
Updated: 1/1/1970
GSK Investigational Site
mi
from
Washington,
A Phase II, Randomized, Open-label Study of Lapatinib Plus Chemotherapy Versus Trastuzumab Plus Chemotherapy in HER2-positive and p95HER2-positive Metastatic Breast Cancer
A Phase II, Randomized, Open-label Study of Lapatinib Plus Chemotherapy Versus Trastuzumab Plus Chemotherapy as First-line Treatment for Women With HER2-positive and p95HER2-positive Metastatic Breast Cancer
Status: Archived
GSK Investigational Site
mi
from
Roswell, GA
A Phase II, Randomized, Open-label Study of Lapatinib Plus Chemotherapy Versus Trastuzumab Plus Chemotherapy in HER2-positive and p95HER2-positive Metastatic Breast Cancer
A Phase II, Randomized, Open-label Study of Lapatinib Plus Chemotherapy Versus Trastuzumab Plus Chemotherapy as First-line Treatment for Women With HER2-positive and p95HER2-positive Metastatic Breast Cancer
Status: Archived
Updated: 1/1/1970
GSK Investigational Site
mi
from
Roswell, GA
A Phase II, Randomized, Open-label Study of Lapatinib Plus Chemotherapy Versus Trastuzumab Plus Chemotherapy in HER2-positive and p95HER2-positive Metastatic Breast Cancer
A Phase II, Randomized, Open-label Study of Lapatinib Plus Chemotherapy Versus Trastuzumab Plus Chemotherapy as First-line Treatment for Women With HER2-positive and p95HER2-positive Metastatic Breast Cancer
Status: Archived
McFarland Clinic, PC
mi
from
Ames, IA
A Phase II, Randomized, Open-label Study of Lapatinib Plus Chemotherapy Versus Trastuzumab Plus Chemotherapy in HER2-positive and p95HER2-positive Metastatic Breast Cancer
A Phase II, Randomized, Open-label Study of Lapatinib Plus Chemotherapy Versus Trastuzumab Plus Chemotherapy as First-line Treatment for Women With HER2-positive and p95HER2-positive Metastatic Breast Cancer
Status: Archived
Updated: 1/1/1970
McFarland Clinic, PC
mi
from
Ames, IA
A Phase II, Randomized, Open-label Study of Lapatinib Plus Chemotherapy Versus Trastuzumab Plus Chemotherapy in HER2-positive and p95HER2-positive Metastatic Breast Cancer
A Phase II, Randomized, Open-label Study of Lapatinib Plus Chemotherapy Versus Trastuzumab Plus Chemotherapy as First-line Treatment for Women With HER2-positive and p95HER2-positive Metastatic Breast Cancer
Status: Archived
Hospital of the University of Pennsylvania
mi
from
Philadelphia, PA
A Phase II, Randomized, Open-label Study of Lapatinib Plus Chemotherapy Versus Trastuzumab Plus Chemotherapy in HER2-positive and p95HER2-positive Metastatic Breast Cancer
A Phase II, Randomized, Open-label Study of Lapatinib Plus Chemotherapy Versus Trastuzumab Plus Chemotherapy as First-line Treatment for Women With HER2-positive and p95HER2-positive Metastatic Breast Cancer
Status: Archived
Updated: 1/1/1970
Hospital of the University of Pennsylvania
mi
from
Philadelphia, PA
A Phase II, Randomized, Open-label Study of Lapatinib Plus Chemotherapy Versus Trastuzumab Plus Chemotherapy in HER2-positive and p95HER2-positive Metastatic Breast Cancer
A Phase II, Randomized, Open-label Study of Lapatinib Plus Chemotherapy Versus Trastuzumab Plus Chemotherapy as First-line Treatment for Women With HER2-positive and p95HER2-positive Metastatic Breast Cancer
Status: Archived
GSK Investigational Site
mi
from
Exeter, NH
A Phase II, Randomized, Open-label Study of Lapatinib Plus Chemotherapy Versus Trastuzumab Plus Chemotherapy in HER2-positive and p95HER2-positive Metastatic Breast Cancer
A Phase II, Randomized, Open-label Study of Lapatinib Plus Chemotherapy Versus Trastuzumab Plus Chemotherapy as First-line Treatment for Women With HER2-positive and p95HER2-positive Metastatic Breast Cancer
Status: Archived
Updated: 1/1/1970
GSK Investigational Site
mi
from
Exeter, NH
A Phase II, Randomized, Open-label Study of Lapatinib Plus Chemotherapy Versus Trastuzumab Plus Chemotherapy in HER2-positive and p95HER2-positive Metastatic Breast Cancer
A Phase II, Randomized, Open-label Study of Lapatinib Plus Chemotherapy Versus Trastuzumab Plus Chemotherapy as First-line Treatment for Women With HER2-positive and p95HER2-positive Metastatic Breast Cancer
Status: Archived
GSK Investigational Site
mi
from
Cherry Hill, NJ
A Phase II, Randomized, Open-label Study of Lapatinib Plus Chemotherapy Versus Trastuzumab Plus Chemotherapy in HER2-positive and p95HER2-positive Metastatic Breast Cancer
A Phase II, Randomized, Open-label Study of Lapatinib Plus Chemotherapy Versus Trastuzumab Plus Chemotherapy as First-line Treatment for Women With HER2-positive and p95HER2-positive Metastatic Breast Cancer
Status: Archived
Updated: 1/1/1970
GSK Investigational Site
mi
from
Cherry Hill, NJ
A Phase II, Randomized, Open-label Study of Lapatinib Plus Chemotherapy Versus Trastuzumab Plus Chemotherapy in HER2-positive and p95HER2-positive Metastatic Breast Cancer
A Phase II, Randomized, Open-label Study of Lapatinib Plus Chemotherapy Versus Trastuzumab Plus Chemotherapy as First-line Treatment for Women With HER2-positive and p95HER2-positive Metastatic Breast Cancer
Status: Archived
West Virginia University Hospitals Inc.
mi
from
Morgantown, WV
A Phase II, Randomized, Open-label Study of Lapatinib Plus Chemotherapy Versus Trastuzumab Plus Chemotherapy in HER2-positive and p95HER2-positive Metastatic Breast Cancer
A Phase II, Randomized, Open-label Study of Lapatinib Plus Chemotherapy Versus Trastuzumab Plus Chemotherapy as First-line Treatment for Women With HER2-positive and p95HER2-positive Metastatic Breast Cancer
Status: Archived
Updated: 1/1/1970
West Virginia University Hospitals Inc.
mi
from
Morgantown, WV
A Phase II, Randomized, Open-label Study of Lapatinib Plus Chemotherapy Versus Trastuzumab Plus Chemotherapy in HER2-positive and p95HER2-positive Metastatic Breast Cancer
A Phase II, Randomized, Open-label Study of Lapatinib Plus Chemotherapy Versus Trastuzumab Plus Chemotherapy as First-line Treatment for Women With HER2-positive and p95HER2-positive Metastatic Breast Cancer
Status: Archived
GSK Investigational Site
mi
from
Fargo, ND
A Phase II, Randomized, Open-label Study of Lapatinib Plus Chemotherapy Versus Trastuzumab Plus Chemotherapy in HER2-positive and p95HER2-positive Metastatic Breast Cancer
A Phase II, Randomized, Open-label Study of Lapatinib Plus Chemotherapy Versus Trastuzumab Plus Chemotherapy as First-line Treatment for Women With HER2-positive and p95HER2-positive Metastatic Breast Cancer
Status: Archived
Updated: 1/1/1970
GSK Investigational Site
mi
from
Fargo, ND
A Phase II, Randomized, Open-label Study of Lapatinib Plus Chemotherapy Versus Trastuzumab Plus Chemotherapy in HER2-positive and p95HER2-positive Metastatic Breast Cancer
A Phase II, Randomized, Open-label Study of Lapatinib Plus Chemotherapy Versus Trastuzumab Plus Chemotherapy as First-line Treatment for Women With HER2-positive and p95HER2-positive Metastatic Breast Cancer
Status: Archived
GSK Investigational Site
mi
from
Knoxville, TN
A Phase II, Randomized, Open-label Study of Lapatinib Plus Chemotherapy Versus Trastuzumab Plus Chemotherapy in HER2-positive and p95HER2-positive Metastatic Breast Cancer
A Phase II, Randomized, Open-label Study of Lapatinib Plus Chemotherapy Versus Trastuzumab Plus Chemotherapy as First-line Treatment for Women With HER2-positive and p95HER2-positive Metastatic Breast Cancer
Status: Archived
Updated: 1/1/1970
GSK Investigational Site
mi
from
Knoxville, TN
A Phase II, Randomized, Open-label Study of Lapatinib Plus Chemotherapy Versus Trastuzumab Plus Chemotherapy in HER2-positive and p95HER2-positive Metastatic Breast Cancer
A Phase II, Randomized, Open-label Study of Lapatinib Plus Chemotherapy Versus Trastuzumab Plus Chemotherapy as First-line Treatment for Women With HER2-positive and p95HER2-positive Metastatic Breast Cancer
Status: Archived
GSK Investigational Site
mi
from
Austin, TX
A Phase II, Randomized, Open-label Study of Lapatinib Plus Chemotherapy Versus Trastuzumab Plus Chemotherapy in HER2-positive and p95HER2-positive Metastatic Breast Cancer
A Phase II, Randomized, Open-label Study of Lapatinib Plus Chemotherapy Versus Trastuzumab Plus Chemotherapy as First-line Treatment for Women With HER2-positive and p95HER2-positive Metastatic Breast Cancer
Status: Archived
Updated: 1/1/1970
GSK Investigational Site
mi
from
Austin, TX
A Phase II, Randomized, Open-label Study of Lapatinib Plus Chemotherapy Versus Trastuzumab Plus Chemotherapy in HER2-positive and p95HER2-positive Metastatic Breast Cancer
A Phase II, Randomized, Open-label Study of Lapatinib Plus Chemotherapy Versus Trastuzumab Plus Chemotherapy as First-line Treatment for Women With HER2-positive and p95HER2-positive Metastatic Breast Cancer
Status: Archived
GSK Investigational Site
mi
from
La Crosse, WI
A Phase II, Randomized, Open-label Study of Lapatinib Plus Chemotherapy Versus Trastuzumab Plus Chemotherapy in HER2-positive and p95HER2-positive Metastatic Breast Cancer
A Phase II, Randomized, Open-label Study of Lapatinib Plus Chemotherapy Versus Trastuzumab Plus Chemotherapy as First-line Treatment for Women With HER2-positive and p95HER2-positive Metastatic Breast Cancer
Status: Archived
Updated: 1/1/1970
GSK Investigational Site
mi
from
La Crosse, WI